Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old

Milena Gusella,A. Bononi,Yasmina Modena,Laura Bertolaso,Paola Franceschetti,D. Menon,E. Pezzolo,Carmen Barile,Giorgio Crepaldi,Caterina Bolzonella,Alessandro Inno,Roberto Padrini,Felice Pasini

Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old

2014

Milena Gusella
A. Bononi
Yasmina Modena
Laura Bertolaso
Paola Franceschetti
D. Menon
E. Pezzolo
Carmen Barile
Giorgio Crepaldi
Caterina Bolzonella
Alessandro Inno
Roberto Padrini
Felice Pasini

Purpose Pegylated liposomal doxorubicin (PLD) is often used in elderly people, due to its improved tolerability. However, clinical and pharmacological data in the subset of patients over 70 are scanty.

Keywords:

Pegylated Liposomal Doxorubicin
Liposome
Pharmacology
Doxorubicin
Medicine
Tolerability
Pharmacokinetics
elderly people
pharmacology toxicology
in patient
drug toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations